Thalidomide costimulates primary human t lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

Journal of Experimental Medicine

Volumn 187, Issue 11, 1998, Pages 1885-1892

  Haslett, Patrick A J ^a   Corral, Laura G ^a   Albert, Matthew ^a   Kaplan, Gilla ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

CD8+; Costimulation T cells; Pharmacologic immune modulation; Thalidomide

Indexed keywords

CD8 ANTIGEN; THALIDOMIDE;

ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFECT; ERYTHEMA NODOSUM LEPROSUM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEPROSY; LYMPHOCYTE COUNT; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD3; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; ENTEROTOXINS; FIXATIVES; GLUTARAL; HUMANS; MITOGENS; SUPERANTIGENS; THALIDOMIDE;

EID: 0032100486     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.187.11.1885     Document Type: Article

References (37)

1. Sheskin, J. 1965. Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther. 6:303-306.
2. Sampaio, E.P., G. Kaplan, A. Miranda, J.A. Nery, C.P. Miguel, S.M. Viana, and E.N. Sarno. 1993. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. 168:408-414.
3. Sampaio, E.P., E.N. Sarno, R. Galilly, Z.A. Cohn, and G. Kaplan. 1991. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J. Exp. Med. 173:699-703.
4. Waters, M.F.R. 1971. An internally controlled double-blind trial of thalidomide in severe erythema nodosum leprosum. Lepr. Rev. 42:26-42.
5. Jacobson, J.M., J.S. Greenspan, J. Spritzler, N. Ketter, J.L. Fahey, J.B. Jackson, L. Fox, M. Chernoff, A.W. Wu, L.A. MacPhail, et al. 1991. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N. Engl. J. Med. 336:1487-1493.
6. Alexander, L.N., and C.M. Wilcox. 1997. A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. AIDS Res. Hum. Retroviruses. 13:301-304.
7. McCarthy, D.M., E.J. Kanfer, and A.J. Barrett. 1989. Thalidomide for the therapy of chronic graft-versus-host disease following allogeneic bone marrow transplantation. Biomed. Pharmacother. 43:693-697.
8. Vogelsang, G.B., E.R. Farmer, A.D. Hess, V. Altamonte, W.E. Beschorner, D.A. Jabs, R.L. Corio, L.S. Levin, O.M. Colvin, J.R. Wingard, et al. 1992. Thalidomide for the treatment of chronic graft-versus-host disease. N. Engl. J. Med. 326:1055-1058.
9. Mueller, D.L., M.K. Jenkins, and R.H. Schwartz. 1989. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7: 445-480.
10. Linsley, P.S., KM. Wallace, J. Johnson, M.G. Gibson, J.L. Greene, J.A. Ledbetter, C. Singh, and M.A. Tepper. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science. 257:792-795.
11. Bender, A., M. Sapp, G. Schuler, R.M. Steinman, and N. Bhardwaj. 1996. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods. 196:121-135.
12. Young, J.W., and R.M. Steinman. 1990. Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells. J. Exp. Med. 171:1315-1332.
13. Jenkins, M.K., J.D. Ashwell, and R. Schwartz. 1988. Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J. Immunol. 140:3324-3330.
14. Roska, A.K., and P.E. Lipsky. 1985. Dissection of the functions of antigen-presenting cells in the induction of T cell activation. J. Immunol. 135:2953-2961.
15. Tramontane J.M., U. Utaipat, A. Molloy, P. Akarasewi, M. Burroughs, S. Makonkawkeyoon, B. Johnson, J.D. Klausner, W. Rom, and G. Kaplan. 1995. Thalidomide treatment reduces tumor necrosis factor α production and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med. 1:384-397.
16. Nogueira, A.C., R. Neubert, H. Helge, and D. Neubert. 1994. Thalidomide and the immune response. 3. Simultaneous up-and down-regulation of different integrin receptors on human white blood cells. Life Sci. 55:77-92.
17. McHugh, S.M., I.R. Rifkin, J. Deighton, A.B. Wilson, P.J. Lachmann, C.M. Lockwood, and P.W. Ewan. 1995. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen-and antigen-stimulated human peripheral blood mononuclear cell cultures. Exp. Immunol. 99: 160-167.
18. Moller, D.R., M. Wysocka, B.M. Greenlee, X. Ma, L. Wahl, D.A. Flockhart, G. Trinchieri, and C.L. Karp. 1997. Inhibition of IL-12 production by thalidomide. J. Immunol. 159: 5157-5161.
19. D'Amato, R.J., M.S. Loughnan, E. Flynn, and J. Folkman. 1994. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA. 91:4082-4085.
20. Field, E.O., J.E. Gibbs, D.F. Tucker, and K. Hellman. 1966. Effect of thalidomide on the graft versus host reaction. Nature. 211:1308-1310.
21. Vogelsang, G.B., A. Hess, G. Gordon, and G.W. Santos. 1986. Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. Transplantation (Baltimore). 41:644-647.
22. Vogelsang, G.B., A.D. Hess, G. Gordon, R. Brundrette, and G.W. Santos. 1987. Thalidomide induction of bone marrow transplantation tolerance. Transplant. Proc. 19:2658-2661.
23. Keenan, R.J., G. Eiras, G.J. Burckart, R.S. Stuart, R.L. Hardesty, G. Vogelsang, B.P. Griffith, and A. Zeevi. 1991. Immunosuppressive properties of thalidomide. Transplantation (Baltimore). 52:908-910.
24. Coulson AS., L.J. Summers, K. Lindahl-Kiessling, D. Tucker, and K. Hellman. 1970. The effects of two soluble thalidomide derivatives on lymphocyte stimulation. Clin. Exp. Immunol. 7:241-247.
25. Fernandez, L.P., P.G. Schlegel, J. Baker, Y. Chen, and N.J. Chao. 1995. Does thalidomide affect IL-2 response and production? Exp. Hematol. 23:978-985.
26. Chen, T.-L., G.B. Vogelsang, B.G. Petty, K.B. Brundrett, D.A. Noe, G.W. Santos, and O.M. Colvin. 1989. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab. Dispos. 17:402-405.
27. Shannon, E.J., and F. Sandoval. 1995. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology. 31:109-116.
28. Östraat, O., K. Riesbeck, Z. Qi, T. Eriksson, H. Schatz, and H. Ekberg. 1996. Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory effect on lymphocyte function in vitro. Transplant Immunol. 4:117-125.
29. Haslett, P., M. Hempstead, C. Seidman, J. Diakun, D. Vasquez, V.H. Freedman, and G. Kaplan. 1997. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res. Hum. Retroviruses. 13:1047-1053.
30. Bloom, B.R., R.L. Modlin, and P. Salgame. 1992. Stigma variations: observations on suppressor T cells and leprosy. Annu. Rev. Immunol. 10:453-488.
31. Koh, D.R., W.P. Fung-Leung, A. Ho, D. Gray, H. Acha-Orbea, and T.W. Mak. 1992. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/-mice. Science. 256:1210-1213.
32. Ware, R., H. Jiang, N. Braunstein, J. Kent, E. Wiener, B. Pernis, and L. Chess. 1995. Human CD8+ T lymphocyte clones specific for T cell receptor Vβ families expressed on autologous CD4+ T cells. Immunity. 2:177-184.
33. Hoang, P., H.R. Dalton, and D.P. Jewell. 1991. Human colonic intra-epithelial cells are suppressor cells. Clin. Exp. Immunol. 85:498-503.
34. Mayer, L., and D. Eisenhardt. 1990. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J. Clin. Invest. 86:1255-1260.
35. Waters, M.F.R., A.B.C. Laing, A. Ambikapathy, and J.E. Lennard-Jones. 1979. Treatment of ulcerative colitis with thalidomide. Brit. Med. J. 1:792.
36. Wettstein, A.R., and A.P. Meagher. 1997. Thalidomide in Crohn's disease. Lancet. 350:1445-1446.
37. Stack, W.A., S.D. Mann, A.J. Roy, P. Heath, M. Sopwith, J. Freeman, G. Holmes, R. Long, A. Forbes, and M.A. Kamm. 1997. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet. 349: 521-524.